118 results about "Systemic toxicity" patented technology

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The invention discloses a glucan-based MMAE conjugate as well as a preparation method and application thereof, and relates to the technical field of medicines. The conjugate takes glucan with good biocompatibility as a carrier, and is covalently connected with a cytotoxic drug MMAE through a VC peptide linker capable of being cut by cathepsin B. The conjugate has good serum stability, can specifically release drugs at a tumor site, and realizes efficient tumor uptake by virtue of the stealth effect of glucan and potential GLUT1 targeting. In-vitro and animal experiments show that the conjugate has a remarkable treatment effect on pancreatic cancer and is low in systemic toxicity.

The invention discloses in-situ drug-loaded synergistic treatment gel P-GFe-coated Gel as well as a preparation method and application thereof, and belongs to the field of biological medicines. By integrating the photo-thermal characteristics of mesoporous polydopamine (MPDA), the CDT efficiency of Fe, the TME regulation effect of glucose oxidase (GOx) and the in-situ delivery capacity of protein hydrogel, PTT / CDT synergistic treatment is achieved, and the problems that in existing tumor treatment, targeting is insufficient, the curative effect is limited by TME, and systemic toxicity is high are solved. The preparation technology is simple and mild, raw materials are easy to obtain, large-scale production can be achieved, and wide application prospects are achieved in clinical treatment of malignant tumors such as breast cancer.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

The invention belongs to the technical field of biological medicines, and particularly provides an ALO-coated F127-MOF nano-composite as well as a preparation method and application thereof. According to the ALO (at) F127-MOF nano compound, UiO-66-NH2 MOF with a pluronic F-127 coating is used as a nano carrier, and aloperine is loaded on the nano carrier. The nano compound is used for treating ALI, the solubility, stability and bioavailability of the traditional Chinese medicine aloperine are effectively improved, and the synergistic effect of sustained release of aloperine, ROS neutralization and effective targeting is achieved. The aerosolization-based delivery approach ensures better oxygenation, lower systemic toxicity, and better pulmonary deposition. The invention provides a new treatment method for noninvasive acute lung injury treatment.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention discloses an application of an engineered mRNA (messenger Ribonucleic Acid) medicine for coding COL3A1 protein in resisting skin photoaging. According to the method, accurate rational design and optimization are carried out on the 5'untranslated region (UTR) of the hCOL3A1 mRNA, so that the translation efficiency and the protein yield of the hCOL3A1 mRNA are greatly improved, the expression level of the hCOL3A1 target protein far beyond the conventional sequence in vivo and in vitro is realized, and the type III collagen is efficiently and endogenously synthesized in skin cells. Experimental results show that the engineered mRNA can effectively reduce the skin oxidative stress level, inhibit cell aging and promote endogenous synthesis and deposition of corium layer collagen, so that the barrier function of photoaged skin is remarkably improved, the dermis thickness is increased, the tissue structure is repaired, and systemic toxicity or immune side effects are not observed. The invention provides a novel strategy with high efficiency and safety for resisting skin photoaging.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

The application discloses a new use of androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, namely, application of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in preparation of a medicine for treating lymphoma. 50 The IC value of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in the SR cell line is detected by a CCK-8 method, and the cytotoxicity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione on human umbilical vein endothelial cells Huvce and human immortalized keratinocytes Hacat is detected, in the body, the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione significantly inhibits tumor growth and shows good biological safety and no systemic toxicity; TUNEL staining, gamma-H2AX staining and neutral comet experiment prove that the compound of the application inhibits the growth of SR by causing serious damage to DNA, the application not only adds the diversity of the biological activity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, but also provides a new direction for developing a new medicine for treating lymphoma.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

This application relates to the field of pharmaceutical technology, and in particular to a topical ointment formulation and its preparation method. The formulation uses Sonicate as the active ingredient, combined with petrolatum, liquid paraffin, a solubilizing and penetration-enhancing system, and emulsifiers as excipients, to form an O / W type cream, an oil-based or water-soluble ointment. The preparation process employs a low-temperature dosing method at 40°C to ensure drug activity and inhibit crystallization. This application achieves high-concentration retention in local skin tissue through topical administration, significantly reducing radiation damage scores and pathological damage, while resulting in extremely low systemic plasma exposure, avoiding the systemic toxicity of oral administration, and providing a safe and efficient means for the clinical prevention and treatment of radiation-induced skin damage.

The invention discloses an anti-cervical cancer nano targeting tablet based on a traditional Chinese medicine compound and a preparation method thereof. The nano targeting tablet is prepared from the following raw materials in parts by weight: centipede, bungarus parvus, syngnathus, scorpio, nidus vespae, leech, ground beeltle, frankincense, myrrh, dandelion, rhizoma cyperi, radix bupleuri, fructus aurantii, cortex phellodendri, angelica sinensis, radix curcumae, poria cocos, bighead atractylodes rhizome, radix paeoniae alba, cortex albiziae, Chinese yam, oldenlandia diffusa and selfheal. According to the invention, active ingredients of the traditional Chinese medicinal materials are retained and enriched to the maximum extent through a modern extraction technology, the curative effect of the original formula is ensured to be retained to the maximum extent, and through a folic acid receptor, CD44 receptor and pH sensitive triple targeting mechanism, the medicine is enriched in cervical cancer tissues, the local medicine concentration is improved, the system toxicity is reduced, and accurate targeting delivery is realized.

The invention relates to a composition for tumor local injection, a medical and mechanical combined product and application of the composition in preparation of a medicine for tumor local injection administration. The composition comprises an antitumor drug component, an immunologic adjuvant and a drug carrier. By means of the jet flow microneedle delivery device which is specially designed, tumor local drug delivery of anti-tumor drugs can be achieved, and the problem that the maximum drug dosage and the treatment effect are limited due to system toxicity in traditional intravenous drug delivery is solved. The high-concentration local administration of the composition provided by the invention not only improves the local treatment effect of tumors, but also can effectively generate tumor antigens. The tumor antigen generated in situ can be matched with an immunologic adjuvant in the composition to generate tumor specific immune cells on the premise that the immune system of a patient is not damaged due to the toxicity of a drug system, so that the immune response of the local part and the whole body of the patient to tumors is improved. Besides, in the subsequent treatment course after the initial treatment, only the composition of the immunologic adjuvant and the tumor specific polypeptide or the immunologic adjuvant can be given to maintain and enhance the established tumor specific immune response, and accumulated toxicity caused by repeated use of chemotherapeutic drugs is avoided.

The application discloses a stable liver cancer embolism emulsion of raltitrexed drug gel and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The emulsion is composed of iodized oil embolism agent and raltitrexed drug gel; the raltitrexed drug gel is a nanofiber network hydrogel formed by self-assembly of raltitrexed molecules in an aqueous phase through ultrasonic treatment, and simultaneously serves as an active pharmaceutical ingredient and an emulsion stabilizer. The iodized oil and the raltitrexed drug gel are physically mixed and injected through a three-way valve to form a stable oil-in-water emulsion or a water-in-oil emulsion, and any additional chemical surfactant or cosolvent is not needed. The emulsion has excellent physical stability, and can effectively solve the problems of easy aggregation and sedimentation of a traditional iodized oil emulsion and increased systemic toxicity caused by drug burst release. The emulsion has good embolism effect and drug release behavior, can significantly inhibit tumor growth, and has a wide clinical transformation prospect.

Provided are drug-device combinations and methods used for direct delivery of therapeutic drugs to the pituitary gland, wherein the drug-device combination also acts as a barrier between a sella turcica (pituitary fossa) and a sphenoid sinus to effectively trap or confine the drug substance within the sella turcica to prevent its premature escape away into the CSF from the target pituitary; thereby reducing or eliminating systemic toxicity of the drug substance. The drug-device combination includes a cap, a stem, a drug that is therapeutically effective for a pituitary gland disorder.

The present application relates to the technical field of medicine, and in particular to a budesonide-loaded oral colon-targeted delivery system, a preparation method and application. The delivery system takes Pickering emulsion-encapsulated budesonide as the core, and is sequentially coated with a low-ester pectin-calcium ion crosslinked inner layer and a low-ester pectin-chitosan polyelectrolyte complex outer layer. The preparation process is realized by combining an emulsion template method with layer-by-layer self-assembly technology. The obtained microcapsules have a uniform spherical structure, a particle size of about 400 μm, and a double-layer three-dimensional network structure. The delivery system remains stable in the gastrointestinal environment, and only releases drugs rapidly under colon pH conditions. In vitro simulation experiments show that the drug release rate is less than 5% in the stomach / small intestine stage, and is rapidly released in the colon stage. Animal experiments confirm that the effect of treating ulcerative colitis is equivalent to that of mesalamine, while the systemic toxicity is significantly reduced, the drug retention time at the colon site is more than 24 hours, and there is no accumulation in non-target organs.

The invention discloses a PD-L1 cell targeting fusion protein connected in series with a TGFBR2 extracellular domain, IL-2 and a receptor thereof, and an application thereof. Belongs to the technical field of biology. The fusion protein provided by the invention is a heterotetramer formed by connecting two similar heavy polypeptide chains and two similar light polypeptide chains through a disulfide bond. The fusion protein realizes triple functions through a single molecule: tumor specific localization is realized through PD-L1 targeting VHH (Vascular Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus Haemophilus); an immunosuppressive factor TGF-beta in a tumor microenvironment is neutralized through TGFBR2 ECD; effect immune cells expressing a medium affinity IL-2 receptor are selectively activated and amplified by the combination of IL-2 and IL-2R alpha. The PD-L1 inhibitor provided by the invention overcomes the multiple problems of limited curative effect of a single drug, high IL-2 systemic toxicity, tumor microenvironment immunosuppression and the like in the existing PD-(L) 1 inhibitor, and provides technical support for detection, prevention and treatment of PD-L1 positive tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to a bladder cancer targeted nano-drug and a preparation method thereof. The drug is constructed by taking a chemotherapeutic drug gemcitabine-loaded poly (lactic-co-glycolic acid) nanoparticle as a core and assembling two functional components, namely a gadolinium-doped zinc-aluminum layered double hydroxide folic acid conjugate and a bismuth-tellurium alloy nano-cluster hyaluronic acid compound, on the surface of the nanoparticle. During preparation, the drug-loaded nanoparticles are prepared by adopting a multiple emulsion solvent evaporation method, and then the two functional compounds are co-assembled on the surfaces of the drug-loaded nanoparticles by utilizing electrostatic interaction to form the multifunctional hybrid shell layer. The nano-drug integrates multiple functions such as active targeting, microenvironment response drug release, multi-mode imaging, chemotherapy and chemical kinetics combined treatment and radiotherapy sensitization, enrichment and permeation of the drug at a bladder tumor part can be remarkably improved, efficient synergistic treatment is achieved, system toxicity is reduced, and the nano-drug is particularly suitable for perfusion treatment in the bladder.

The invention discloses a hypoxia activating peptide-photosensitizer-drug conjugate and a preparation method and application thereof in the technical field of medicine, the conjugate takes indocyanine with a high molar extinction coefficient as a photosensitive core, distorted conjugate units are introduced to two sides of indole, the characteristic of'limited movement in molecules' is given to the conjugate, and radiation and non-radiation energy dissipation are balanced. Meanwhile, an azo bond sensitive to hypoxia is reasonably introduced between a light treatment module and a chemotherapy module to serve as a responsive linker, and is further coupled with two-molecule integrin targeting peptide cRGD, so that the azo bond is self-assembled into nanospheres in an aqueous solution, and a triple targeting mechanism, namely multivalent integrin receptor targeting, aggregation and tumor microenvironment hypoxia selective activation, is realized. In an in-situ osteosarcoma mouse model, the conjugate realizes real-time near-infrared two-region imaging, shows potent tumor inhibition, effectively inhibits lung metastasis, and does not detect obvious systemic toxicity.

The application discloses an siRNA targeting ACADL, a lipid nanoparticle containing the same and application thereof. The application also relates to a pharmaceutical composition containing the lipid nanoparticle and use of an agent for inhibiting ACADL in preparation of a drug for treating peritoneal metastasis of colorectal cancer. The siRNA and the lipid nanoparticle containing the same can effectively inhibit cancer cell proliferation and invasion, reduce tumor load of peritoneal metastasis foci and have the advantages of selectively knocking down tumor ACADL expression and reducing systemic toxicity by targeting inhibition of a fatty acid oxidation (FAO) process of tumor cells.

The invention discloses a preparation method and application of an iron-copper diatomic nano-enzyme, and relates to a preparation method and application of a nano-enzyme. The invention aims to solve the problem that the clinical application of the traditional treatment means is often limited and challenged by severe systemic toxicity, drug resistance and tumor recurrence although the traditional treatment means improve the survival rate of patients. The method comprises the following steps: 1, dissolving dimethylimidazole in absolute methanol, and stirring to obtain a solution A; step 2, dissolving zinc nitrate hexahydrate, ferric ammonium citrate and copper acetylacetonate in absolute methanol, and stirring to obtain a solution B; 3, mixing and stirring the solution A and the solution B, centrifuging, washing and drying to obtain a white sample ZIF-8; and step 4, pyrolyzing the white sample ZIF-8 at 900 DEG C to obtain black powder, namely the iron-copper diatomic nano-enzyme. The invention belongs to the technical field of active oxygen mediated tumor treatment.

The invention relates to a proportion-locked in-situ gel for tumor chemoimmunotherapy as well as a preparation method and application of the proportion-locked in-situ gel. The in-situ gel comprises a pharmaceutical composition and sodium alginate (ALG), wherein the pharmaceutical composition is composed of gemcitabine (GEM), oxaliplatin (OXA) and cytidine deaminase inhibitor chidauridine (CDZ), and the sodium alginate (ALG) is used as a carrier. The in-situ gel is subjected to intratumor injection and then gelation is triggered by Ca < 2 + > in a tumor, so that local retention and synchronous slow release of the medicine are realized. Metabolic inactivation of GEM is inhibited through CDZ, the optimal treatment proportion of GEM and OXA is maintained at the tumor site, and meanwhile the in-situ gel solves the problems of systemic toxicity and proportion imbalance caused by traditional intravenous administration. The synergistic effect of the pharmaceutical composition not only enhances direct cytotoxicity, but also synergistically activates anti-tumor immune response through OXA-induced immunogenic cell death and GEM-mediated regulatory T cell depletion. The invention realizes safe and efficient local chemical immunotherapy, and has a good clinical application prospect.

The invention relates to an active oxygen degradable polydiacetylene prodrug as well as preparation and application thereof, and belongs to the technical field of medicines. By utilizing the unique property that a main chain of a polydiacetylene polymer is completely broken into carboxyl-containing small molecules when the active oxygen level is increased, a carboxyl-containing drug is used as a raw material to construct a polydiacetylene prodrug, so that long-acting on-demand drug release of active oxygen response is realized. According to the prodrug, active oxygen is utilized to trigger a conjugated main chain to break so as to release an active drug, and meanwhile, a biocompatible small molecule by-product is generated. According to the polydiacetylene polymer side chain covalent connection medicine carrying system, the phenomenon of burst release of the medicine is effectively avoided, continuous administration as long as several months is achieved, and the polydiacetylene polymer side chain covalent connection medicine carrying system has high focus site selectivity and extremely low systemic toxicity. The active oxygen responsive degradation process and drug release cooperate to play a therapeutic role, and a negative feedback regulation drug release loop is formed, so that excessive administration and whole body exposure are avoided, on-demand remodeling of a microenvironment is realized, and the therapeutic effect is improved.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The application provides a pH and near-infrared light dual-response photocage compound and application thereof. The photocage compound comprises a silicon-xanthene ion skeleton and a molecular residue Cargo, and the silicon-xanthene ion skeleton is connected with the Cargo through a Linker. The PPG core skeleton of the application not only responds to near-infrared light irradiation, but also introduces a response mechanism to pH conditions. Compared with the existing PPG which only depends on light triggering, the dual-gating of 'environment (tumor acidity) + external triggering (NIR light)' is realized, the spatiotemporal accuracy and targeting selectivity of active molecule release are significantly improved, and the non-specific release in non-target tissues is reduced, thereby reducing systemic toxicity.